Fintech

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Prnewswire·March 26, 2026 at 11:05 AM

/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Wells Fargo virtual assistant aids over 1 billion transactions
PYMNTS
White House crypto czar joins science advisory committee
CoinDesk
David Sacks leaves crypto post for White House
The Block
Lawmakers Question Bank Regulators on Fintech Rules
PYMNTS

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Wells Fargo virtual assistant aids over 1 billion transactions

White House crypto czar joins science advisory committee

David Sacks leaves crypto post for White House

Lawmakers Question Bank Regulators on Fintech Rules